Market Cap
$3.6B
VCYT
VERACYTE, INC.
$45.55 ▲ +3.08%
Prev close $44.19Market cap$3.6B
ConsensusStrong Buy
12-mo target$58.42 (+28.2%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)31 New Institutional Positions16 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on VCYT right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (84%)
Inst. Holders
50 funds
Inst. Value
$4.4B
Inst. Activity
31 buys / 16 sells
Insider Activity
$0.00 buy / $11.4M sell
Insider Net $
-$11.4M
SEC Reports
12
Press Releases
1
Price chart 30d +1.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: VCYT — 82.3% short (0.4M / 0.5M)
Short: 443,176 | Exempt: 0 | TRF Vol: 538,284 | Short Ratio: 82.3% | Off-exchange volume (dark pool
Sep 21, 2026 Insider
Sep 14, 2026 Press Leite John sold 4,015 shares
Global Chief Commercial Off @ $40.00 ($160.6K)
Veracyte acquires Convergent Genomics for $150M upfront plus up to $30M in milestone payments, adding the UroAmp urinary
Impact 6/10
Sep 14, 2026 Insider
Sep 5, 2026 SEC Holstein Jens sold 5,000 shares
Director @ $40.95 ($204.7K)
Four Veracyte insiders, including the CFO and Chief Scientific & Medical Officer, sold a total of ~$396K in open-market
CLUSTER — Impact 2/10
Sep 4, 2026 Insider
Chambers Rebecca sold 1,175 shares
Chief Financial Officer @ $43.71 ($51.4K)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
1,642,911 shares ($96.5M)
Jun 30, 2026 Inst.
WILLIAM BLAIR INVESTMENT MANAGEMENT, — ADD
1,431,596 shares ($84.1M)
Analyst ratings buy % +6.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
84% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 15, 2026 | Freedom Capital Markets | MAINTAIN | Buy | 46% |
| Sep 9, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 4, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | Stephens & Co. | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | Morgan Stanley | MAINTAIN | Underweight | 55% |
| Aug 3, 2026 | Canaccord Genuity | MAINTAIN | Hold | 47% |
| Jul 31, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 30, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 15, 2026 | Piper Sandler | INITIATE | Overweight | 54% |
| Jul 14, 2026 | Canaccord Genuity | MAINTAIN | Hold | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 8 | 2 | 1 | 0 | 84% | |
| Aug 1, 2026 | 8 | 8 | 2 | 1 | 0 | 84% | |
| Jul 1, 2026 | 8 | 7 | 2 | 1 | 0 | 83% | |
| Jun 1, 2026 | 8 | 7 | 2 | 1 | 0 | 83% | |
| May 1, 2026 | 8 | 8 | 2 | 1 | 0 | 84% | |
| Apr 1, 2026 | 7 | 8 | 3 | 1 | 0 | 79% | |
| Mar 1, 2026 | 7 | 8 | 3 | 1 | 0 | 79% | |
| Feb 1, 2026 | 7 | 8 | 3 | 1 | 0 | 79% |
Price targets
Where 12 covering analysts think VCYT trades over the next 12 months.
$58.42 +28.2% upside Strong Buy
Current$45.55 Low$44.00 Median$59.00 High$70.00 12 analysts
$44.00$70.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 3 bullish, 2 bearish, 0 mixed, 7 neutral · avg impact 4.4/10.Plus 1 press releases.
NEUTRALCLUSTER2/10
Four Veracyte insiders, including the CFO and Chief Scientific & Medical Officer, sold a total of ~$
Sep 5, 2026
NEUTRAL1442/10
Director Karin Eastham filed a Form 144 notice of intent to sell 3,729 shares of Veracyte common sto
Jun 19, 2026
BEARISHCLUSTER5/10
Four Veracyte insiders, including CEO Marc Stapley, sold a combined $7.77M in stock on June 4, 2026.
Jun 15, 2026
BULLISHINST-CLUSTER6/10
A significant institutional cluster in VCYT shows 15 buyers accumulating $175.7M net versus 13 selle
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: VCYT — 82.3% short (0.4M / 0.5M)
Short: 443,176 | Exempt: 0 | TRF Vol: 538,284 | Short Ratio: 82.3% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: VCYT — 60.2% short (0.3M / 0.6M)
Short: 337,519 | Exempt: 880 | TRF Vol: 560,748 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: VCYT — 59.8% short (0.4M / 0.7M)
Short: 443,947 | Exempt: 3,325 | TRF Vol: 742,985 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
other
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and like
Sep 25, 2026
short_volume
Short Volume: VCYT — 68.3% short (0.5M / 0.7M)
Short: 503,876 | Exempt: 40 | TRF Vol: 737,542 | Short Ratio: 68.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.41 | $0.35–$0.45 | -19.3% | -0.3% | 0↑ 9↓ | $0.1B | 12 |
| Next Q | $0.45 | $0.36–$0.50 | -15.5% | -0.3% | 4↑ 5↓ | $0.2B | 12 |
| Current FY | $1.91 | $1.78–$1.99 | 7.5% | +0.4% | 10↑ 0↓ | $0.6B | 12 |
| Next FY | $1.95 | $1.67–$2.11 | 1.9% | +0.1% | 7↑ 3↓ | $0.7B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.412 | — |
| 7d ago | $0.412 | — |
| 30d ago | $0.413 | -0.001 |
| 60d ago | $0.418 | -0.006 |
| 90d ago | $0.433 | -0.021 |
Institutional ownership
Which big funds own VCYT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.4B total value (75,738,245 shares) as of 2026-Q2. Top holders: BlackRock,, FMR, Artisan. Net buying activity: 31 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 13,486,437 | $792.1M | 17.8% | — |
| FMR LLC | 7,702,746 | $452.4M | 10.2% | ADD +35.3% |
| Artisan Partners Limited Partnership | 5,538,404 | $325.3M | 7.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,716,191 | $277.0M | 6.2% | — |
| STATE STREET CORP | 4,698,128 | $276.0M | 6.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,593,922 | $211.1M | 4.7% | — |
| DIMENSIONAL FUND ADVISORS LP | 2,826,524 | $166.0M | 3.7% | — |
| FIRST TRUST ADVISORS LP | 2,507,902 | $147.3M | 3.3% | ADD +64.9% |
| ARK Investment Management LLC | 2,295,951 | $134.8M | 3.0% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 2,274,160 | $133.6M | 3.0% | ADD +25.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | 1,276,260 | 1,642,911 | +28.7% | $96.5M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | ADD | 989,687 | 1,431,596 | +44.7% | $84.1M |
| MORGAN STANLEY | ADD | 797,802 | 1,191,790 | +49.4% | $70.0M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | NEW | — | 1,045,826 | — | $61.4M |
| Sumitomo Mitsui Trust Group, Inc. | TRIM | 1,055,656 | 768,949 | -27.2% | $45.2M |
| Point72 Asset Management, L.P. | ADD | 483,904 | 737,804 | +52.5% | $43.3M |
| Artemis Investment Management LLP | NEW | — | 638,933 | — | $37.5M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 141,811 | 531,572 | +274.8% | $31.2M |
| Alyeska Investment Group, L.P. | TRIM | 808,570 | 518,043 | -35.9% | $30.4M |
| RAYMOND JAMES FINANCIAL INC | ADD | 370,261 | 472,293 | +27.6% | $27.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 50 transactions. Net -$11.4M — $0.00 bought, $11.4M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Leite John | Global Chief Commercial Off | SELL | 4,015 | $40.00 | $160.6K |
| Sep 14, 2026 | Holstein Jens | Director | SELL | 5,000 | $40.95 | $204.7K |
| Sep 4, 2026 | Chambers Rebecca | Chief Financial Officer | SELL | 1,175 | $43.71 | $51.4K |
| Sep 4, 2026 | McGuire Annie | EVP, General Counsel | SELL | 2,154 | $42.79 | $92.2K |
| Sep 4, 2026 | Chambers Rebecca | Chief Financial Officer | SELL | 2,477 | $42.81 | $106.0K |
| Sep 4, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | SELL | 10,405 | $42.89 | $446.3K |
| Sep 4, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | SELL | 2,705 | $43.66 | $118.1K |
| Sep 4, 2026 | McGuire Annie | EVP, General Counsel | SELL | 1,100 | $43.67 | $48.0K |
| Sep 2, 2026 | Febbo Phillip G. | Chief Scientific & Med Officer | TAX W/H | 3,639 | $44.88 | $163.3K |
| Sep 2, 2026 | Chambers Rebecca | Chief Financial Officer | TAX W/H | 3,603 | $44.88 | $161.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VCYT.
Shares short
8,403,932
Settlement Sep 15, 2026
Change vs prior
+4.0%
Semi-monthly cycle
Days to cover
7.8
At avg daily volume
Of shares outstanding
≈10.4%
Estimate — not % of float
All VCYT filing & press-release reports (13)
- PRESS-RELEASE reportSep 14, 2026
- CLUSTER reportSep 5, 2026
- 144 reportJun 19, 2026
- CLUSTER reportJun 15, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportMay 27, 2026
- 144 reportMay 20, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 22, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 6, 2026
- 8-K reportFeb 25, 2026